<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924323</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-MD-60</org_study_id>
    <nct_id>NCT03924323</nct_id>
  </id_info>
  <brief_title>A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Flexibly-dosed, Efficacy and Safety Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder&#xD;
      (GAD) and evaluated using standard questionnaires as having at least moderate severity of&#xD;
      GAD. Participating minors will be assigned to receive either the study drug escitalopram or a&#xD;
      pill without any drug in it called a placebo. The purpose of this research is to study the&#xD;
      safety and effectiveness of escitalopram in minors with GAD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Actual">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pediatric Anxiety Rating Scale (PARS) severity score</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The PARS is a clinician-rated instrument for assessing the severity of anxiety symptoms associated with common anxiety disorders including GAD in children. The PARS severity score for GAD will be assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist derived by summing 5 of the 7 severity/impairment/interference items (2, 3 5, 6, and 7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate on the PARS</measure>
    <time_frame>Week 8</time_frame>
    <description>Response is defined as a 50% improvement on the PARS severity score for GAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate on the PARS</measure>
    <time_frame>Week 8</time_frame>
    <description>Remission is defined as PARS severity score for GAD ≤8 (using 6 PARS items: 2, 3, 4, 5, 6, and 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Remission rate on CGI-S at acute treatment endpoint (Week 8) Remission rate is defined as the percentage of subjects having a CGI-S score ≤2 at endpoint. CGI-S is a seven point scale where 1=Normal and 7=Among the most extremely ill patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the Children's Global Assessment Scale (CGAS)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Remission rate on the CGAS at acute treatment endpoint (Week 8). Functional remission is defined as CGAS &gt;70. The CGAS used is a 100-point scale ranging from 1 to 100, with higher scores indicating better functioning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Anxiety Disorders,Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching oral administration of placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>8-weeks of treatment followed by 1-week taper down period</description>
    <arm_group_label>Escitalopram 10 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral administration of inactive substance once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject's parent/legal representative must give written informed consent, including&#xD;
             privacy authorization, prior to study participation. The subject will complete an&#xD;
             informed assent prior to study participation.&#xD;
&#xD;
          -  Subject meets DSM-5 criteria for a primary diagnosis of GAD at screening established&#xD;
             by a comprehensive psychiatric evaluation and confirmed/supported using the&#xD;
             Mini-International Neuropsychiatric Interview for children and adolescents (MINI Kid).&#xD;
&#xD;
          -  Male subjects who are sexually active with a partner of childbearing potential must&#xD;
             use, with their partner, a condom plus an approved method of highly effective&#xD;
             contraception from the time of informed consent until 14 days after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Female subjects who are sexually active and are of childbearing potential must use,&#xD;
             with their partner, an approved method of highly effective contraception from the time&#xD;
             of informed consent until 14 days after the last dose of study drug.&#xD;
&#xD;
          -  Female subjects who are not of childbearing potential do not need to use any methods&#xD;
             of contraception. This includes preadolescent and adolescent females who have not&#xD;
             reached menarche. - Subject must have venous access enough to allow blood sampling and&#xD;
             be compliant with blood draws as per the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of MDD, attention-deficit/hyperactivity disorder, or lifetime&#xD;
             diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic&#xD;
             disorder, feeding and/or eating disorder, obsessive-compulsive disorder, conduct&#xD;
             disorder, oppositional defiant disorder, post-traumatic stress disorder, panic&#xD;
             disorder, or pervasive development disorder.&#xD;
&#xD;
          -  Suspected or previously diagnosed intellectual disability disorder.&#xD;
&#xD;
          -  One or more first-degree relatives with diagnosed bipolar I disorder.&#xD;
&#xD;
          -  History of seizure disorder (other than febrile seizures).&#xD;
&#xD;
          -  History of electroconvulsive therapy at any time during the subject's lifetime.&#xD;
&#xD;
          -  Known hypersensitivity to escitalopram (escitalopram oxalate) or citalopram or any of&#xD;
             the inactive ingredients or had frequent or severe allergic reactions to multiple&#xD;
             medications.&#xD;
&#xD;
          -  Taking any medications that are contraindicated to escitalopram (escitalopram&#xD;
             oxalate).&#xD;
&#xD;
          -  Inability to speak, read, or understand English well enough to complete the&#xD;
             assessments.&#xD;
&#xD;
          -  No active suicidal ideation or lifetime history of suicidal behavior as assessed by&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harmonex /ID# 233342</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group /ID# 233348</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest, LLC /ID# 233366</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758-6442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc /ID# 233362</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626-4607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group /ID# 233374</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230-6632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center /ID# 233343</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251-9401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers /ID# 233372</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Inst /ID# 233371</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Cen /ID# 233364</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012-4170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare - Jacksonville /ID# 233352</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256-6039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites-Maitland Clinical Research Unit /ID# 233368</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida /ID# 233357</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc /ID# 233350</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801-2986</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APG Research, LLC /ID# 233337</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Rothman Center of Neuropsychiatry /ID# 233356</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701-4708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc. /ID# 233365</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33319-4985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research /ID# 233354</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048-5341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baber Research Group /ID# 233363</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563-6502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates /ID# 233360</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alivation Research /ID# 233338</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526-9474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine Inc /ID# 233355</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128-0819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Behavioral Medicine PLLC /ID# 233351</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research /ID# 233347</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618-1609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Therapeutics of Avon Lake /ID# 233367</name>
      <address>
        <city>Avon Lake</city>
        <state>Ohio</state>
        <zip>44012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research, Inc. /ID# 233375</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 233341</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Cleveland Medical Center /ID# 233373</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center /ID# 233346</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CincyScience /ID# 233359</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Research, PLLC /ID# 233340</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112-8729</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central States Research /ID# 233339</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center /ID# 233344</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials /ID# 233345</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-2928</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials /ID# 233369</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Trials /ID# 233361</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Focus Center, PC /ID# 233349</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405-4946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia /ID# 233370</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center /ID# 233358</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research /ID# 233353</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

